Francis Attiogbe, MD
Internal Medicine · Las Cruces, NMNPI 1457346652
Payments from drug & device makers
Across 37 payments — averaging $18.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$224
- Sanofi-aventis U.S. LLC$158
- AstraZeneca$86
- Pfizer$38
- Shire North American Group Inc$35
- Amarin Pharma, Inc.$22
- plus $120 from 8 others
What the payments were for
- Food & beverage$67298%
- Education$122%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 8 | $224 |
| Sanofi-aventis U.S. LLC | 10 | $158 |
| AstraZeneca | 6 | $86 |
| Pfizer | 2 | $38 |
| Shire North American Group Inc | 2 | $35 |
| Amarin Pharma, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $19 |
| Radius Health, Inc. | 1 | $16 |
| Merck | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
| GSK | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Amgen | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$112
How this compares
$684 in reported general payments places this provider in the 80th percentile of 578 internal medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 129 | $169,445 |
| JardianceEmpagliflozin | 102 | $118,976 |
| JanuviaSitagliptin Phosphate | 53 | $55,696 |
| TrulicityDulaglutide | 41 | $55,245 |
| EliquisApixaban | 57 | $52,694 |
| RybelsusSemaglutide | 31 | $41,332 |
| MounjaroTirzepatide | 20 | $29,882 |
| ProliaDenosumab | 13 | $22,283 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $20,963 |
| TradjentaLinagliptin | 27 | $15,896 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $11,427 |
| MyrbetriqMirabegron | 13 | $11,016 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 63 | $7,602 |
| Repatha SureclickEvolocumab | 11 | $6,074 |
| Levothyroxine Sodium | 329 | $5,228 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Levemir | $224 | $213,288182 claims |
| Boehringer IngelheimJardiance, Tradjenta | $19 | $134,872129 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $15 | $85,12761 claims |
| MerckJanuvia | $16 | $55,69653 claims |
| PfizerEliquis | $38 | $52,69457 claims |
| AmgenProlia | $13 | $22,28313 claims |
| AstraZenecaPulmicort Flexhaler | $86 | $4,25317 claims |
| Sanofi-aventis U.S. LLCLantus | $158 | $2,57819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 578 internal medicine providers in New Mexico.
Other internal medicine in Las Cruces
- Ann MercerLas Cruces$6K
- Sangeeth PaiLas Cruces$4K
- Syed AhmedLas Cruces$3K
- Azhar ZahirLas Cruces$3K
- Talha KhanLas Cruces$3K
- Jobin PhiliposeLas Cruces$2K
- Louis BeneventoLas Cruces$2K
- Edna JuarezLas Cruces$2K
- Michelle ValentineAlbuquerque$12.7M
- Linda GorgosSanta Fe$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.